Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now full pipeline small index

Homozygous Familial Hypercholesterolemia: full-pipeline trial registry

4 of 7 indexed Homozygous Familial Hypercholesterolemia trials are currently recruiting.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

7 US clinical trials · 4 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Homozygous Familial Hypercholesterolemia: 7 US clinical trials tracked, 4 recruiting.

Homozygous Familial Hypercholesterolemia is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Arrowhead Pharmaceuticals, running 2 of these trials.

Enrollment posture brief

Registry condition homozygous-familial-hypercholesterolemia

OPEN 4 | RECR 57% | LATE 2 | EARLY 2 | RANK #2497 | SPON 2

Volume-matched condition peers

Nearest open-share peer: Adverse Childhood Experiences (57% recruiting · 14 trials)

ACL Tear71.4%ACL57.1%Homozygous Familial Hype (th…57%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Homozygous Familial Hypercholesterolemia

Homozygous Familial Hypercholesterolemia lists 4 open slots (57% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Homozygous Familial Hypercholesterolemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Homozygous Familial Hypercholesterolemia is recruiting above its size-band peers.

    4 of 7 indexed trials (57.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Homozygous Familial Hypercholesterolemia research.

    Arrowhead Pharmaceuticals accounts for 2 of 7 trials (28.6%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Homozygous Familial Hypercholesterolemia trials plan to enrol fewer than 100 people.

    Median target enrolment is 60 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.

  4. Homozygous Familial Hypercholesterolemia splits between interventional and observational designs.

    4 interventional and 3 observational studies make up this index (57.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 22Phase 32

Phase Distribution

PhaseTrial count
Phase 2 2
Phase 3 2

Top Sponsors

Arrowhead Pharmaceuticals 2 trials
Aegerion Pharmaceuticals 1 trials
The Rogosin Institute 1 trials
Amryt Pharma 1 trials
Regeneron Pharmaceuticals 1 trials
University of Pennsylvania 1 trials

Named interventions

Most-linked intervention names on Homozygous Familial Hypercholesterolemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Lomitapide Drug
2 trials
Placebo Drug
2 trials
ARO-ANG 3 Injection Drug
1 trials
zodasiran Injection Drug
1 trials
Demographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence. Other
1 trials
Alirocumab Drug
1 trials

US sites by state

Facility locations filed on Homozygous Familial Hypercholesterolemia trials. A trial with sites in several states counts in each.

New York 4 trials
Pennsylvania 3 trials
Ohio 3 trials
Illinois 2 trials
Florida 2 trials
Texas 1 trials
Louisiana 1 trials
Kentucky 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Homozygous Familial Hypercholesterolemia page

7 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 4 Homozygous Familial Hypercholesterolemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Arrowhead Pharmaceuticals sponsors the most Homozygous Familial Hypercholesterolemia trials on record, review their full trial history before evaluating a specific study. See Arrowhead Pharmaceuticals's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Homozygous Familial Hypercholesterolemia condition card totals 7 registered trials; most-linked intervention Lomitapide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.